Atherosclerosis Clinical Trials

Athens : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Birmingham : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Birmingham : Medical Center East

SuperNOVA Clinical Stenting Trial

Fairhope : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Huntsville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Huntsville : Huntsville Hospital - The Heart Center, PC

PROMUS Element Plus US Post-Approval Study

Mobile : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Anchorage : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Glendale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Phoenix : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Phoenix : Carl T. Hayden Medical Research Foundation

SmartRisk Stroke Prediction by MRI of Carotid Disease

Scottsdale : Scottsdale Healthcare Shea

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Hot Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jonesboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jonesboro : NEA Baptist Memorial Hospital

PROMUS Element Plus US Post-Approval Study

Jonesboro : St. Bernard's Medical Center

PROMUS Element Plus US Post-Approval Study

Little Rock : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santa Ana : Coastal Multi-Specialty Research

Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

View More »

Carmichael : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Escondido : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fullerton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Huntington Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lancaster : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Loma Linda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Loma Linda : Loma Linda University Medical Center

PROMUS Element Plus US Post-Approval Study

Long Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Los Angeles : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Los Angeles : Cedars-Sinai Medical Center

SmartRisk Stroke Prediction by MRI of Carotid Disease

Los Angeles : Cedars-Sinai Medical Center

SuperNOVA Clinical Stenting Trial

Los Angeles : University of Southern California

Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)

Los Gatos : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mission Viejo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Northridge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oceanside : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Orangevale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Palm Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pasadena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pomona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Redondo Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sacramento : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sacramento : Mercy General Hospital

PROMUS Element Plus US Post-Approval Study

San Diego : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Francisco : San Francisco Veterans Affairs Medical Center

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

San Francisco : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Francisco : University of California San Francisco

SmartRisk Stroke Prediction by MRI of Carotid Disease

Santa Ana : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santa Clara : Abbott Vascular

Absolute Pro® MOMENTUM™

Santa Rosa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Temecula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Torrance : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Torrance : Los Angeles Biomedical Research Institute

Effect of Aged Garlic Extract on Atherosclerosis

Tustin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Visalia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vista : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Walnut Creek : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Aurora : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Colorado Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Denver : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Longmont : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Waterbury : Chase Medical Research, LLC

Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes

Newark : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newark : Christiana Hospital

PROMUS Element Plus US Post-Approval Study

Washington : Washington Hospital Center

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Washington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brandon : Brandon Regional Hospital

PROMUS Element Plus US Post-Approval Study

Clearwater : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Davie : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Daytona Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Defuniak Springs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Doral : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gainesville : North Florida Regional Medical Center

PROMUS Element Plus US Post-Approval Study

Hollywood : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hollywood : Memorial Regional Hospital

PROMUS Element Plus US Post-Approval Study

Jacksonville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jacksonville : Mayo Clinic Research Unit

Exercise Stress Testing on Peripheral Gene Expression Using CORUS™ CAD Diagnostic Test

Jacksonville Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jupiter : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Miami : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Miami : University of Miami

SmartRisk Stroke Prediction by MRI of Carotid Disease

Miami Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Miami Beach : Mount Sinai Medical Center

PROMUS Element Plus US Post-Approval Study

Naples : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Orlando : Orlando Regional Medical Center

PROMUS Element Plus US Post-Approval Study

Panama City : Bay Medical Center

PROMUS Element Plus US Post-Approval Study

Pinellas Park : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Port Charlotte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Port Orange : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sarasota : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

South Miami : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Stuart : Martin Memorial Health Systems - Martin Memorial Medical Center

PROMUS Element Plus US Post-Approval Study

Tallahassee : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tampa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Trinity : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wellington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Athens : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Atlanta : Piedmont Heart Institute

Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program

Atlanta : Piedmont Hospital

PROMUS Element Plus US Post-Approval Study

Atlanta : St. Joseph's Hospital of Atlanta

SuperNOVA Clinical Stenting Trial

Augusta : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Covington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cumming : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Decatur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Duluth : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gainesville : Northeast Georgia Heart Center

The eMESH 1 Feasibility Study

Macon : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Macon : Coliseum Medical Center

PROMUS Element Plus US Post-Approval Study

Roswell : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Savannah : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Honolulu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Coeur d'Alene : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chicago : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chicago : Northwestern University

Comprehensive Evaluation of Ischemic Heart Disease Using MRI

Chicago : Northwestern University

SmartRisk Stroke Prediction by MRI of Carotid Disease

Jerseyville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lombard : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Oak Lawn : Advocate Christ Medical Center

SuperNOVA Clinical Stenting Trial

Peoria : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Peoria : St. Francis Medical Center

SuperNOVA Clinical Stenting Trial

Quincy : Blessing Hospital

PROMUS Element Plus US Post-Approval Study

Anderson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Carmel : Clarian North Medical Center

PROMUS Element Plus US Post-Approval Study

Evansville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fort Wayne : Parkview Hospital

SuperNOVA Clinical Stenting Trial

Indianapolis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Indianapolis : Franciscan St. Francis Hospital

PROMUS Element Plus US Post-Approval Study

Indianapolis : Indiana Heart Hospital

PROMUS Element Plus US Post-Approval Study

Ames : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Davenport : Genesis Medical Center

SuperNOVA Clinical Stenting Trial

Waterloo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wichita : Via Christi Research

CANTOS: Cardiovascular Risk Reduction Study

View More »

Kansas City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Overland Park : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Topeka : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wichita : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lexington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lexington : St. Joseph Hospital

PROMUS Element Plus US Post-Approval Study

Louisville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Owensboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Baton Rouge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bossier City : Willis Knighton Bossier Medical Center

SuperNOVA Clinical Stenting Trial

Covington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Houma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lafayette : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Mandeville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Metairie : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Orleans : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Orleans : Ochsner Clinic Foundation

SuperNOVA Clinical Stenting Trial

Opelousas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shreveport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shreveport : Cardiovascular Research, LLC

PROMUS Element Plus US Post-Approval Study

Slidell : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Winnsboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Zachary : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bangor : Eastern Maine Medical Center

PROMUS Element Plus US Post-Approval Study

Beltsville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Portland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Towson : Spectrum Clinical Research, Inc.

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

View More »

Baltimore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Baltimore : Sinai Center for Thrombosis Research

Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis

Baltimore : GSK Investigational Site

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

Baltimore : Frederick Memorial Hospital

SuperNOVA Clinical Stenting Trial

Columbia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lutherville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rockville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Boston : Massachusetts General Hospital

Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients

Boston : Massachusetts General Hospital

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

Boston : Tufts Medical Center

SmartRisk Stroke Prediction by MRI of Carotid Disease

Boston : Beth Israel Deaconess Medical Center

SmartRisk Stroke Prediction by MRI of Carotid Disease

Boston : Massachusetts General Hospital

Subclinical Atherosclerosis in HIV-infected Patients

View More »

Boston : Beth Israel Deaconess Medical Center

SuperNOVA Clinical Stenting Trial

Burlington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fall River : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Haverhill : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hyannis : Cape Cod Hospital

PROMUS Element Plus US Post-Approval Study

Natick : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ann Arbor : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chelsea : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Detroit : Wayne State University

SmartRisk Stroke Prediction by MRI of Carotid Disease

East Lansing : Michigan State University

SmartRisk Stroke Prediction by MRI of Carotid Disease

Grand Blanc : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Kalamazoo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Midland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Novi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Petoskey : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Petoskey : Northern Michigan Hospital

SuperNOVA Clinical Stenting Trial

Royal Oak : William Beaumont Hospital

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Royal Oak : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saginaw : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Joseph : Lakeland Hospitals at St. Joseph

PROMUS Element Plus US Post-Approval Study

Troy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wyoming : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bloomington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Coon Rapids : Mercy Hospital

PROMUS Element Plus US Post-Approval Study

Duluth : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Edina : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Minneapolis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Minneapolis : North Memorial Medical Center

PROMUS Element Plus US Post-Approval Study

Minneapolis : Abbott Northwestern Hospital

SuperNOVA Clinical Stenting Trial

Robbinsdale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rochester : Mayo Clinic

Assessment of Coronary Plaque Composition Using Optical Coherence Tomography

Rochester : Mayo Clinic

Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III

Saint Paul : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Cloud : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Paul : United Hospital - St. Paul Heart Clinic

PROMUS Element Plus US Post-Approval Study

Hattiesburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hattiesburg : Forest County General Hospital

PROMUS Element Plus US Post-Approval Study

Jackson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Picayune : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chesterfield : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kansas City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Springfield : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Springfield : St. John's Regional Health Center (Springfield)

PROMUS Element Plus US Post-Approval Study

View More »

Springfield : Cox Medical Centers

PROMUS Element Plus US Post-Approval Study

St. Louis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Grand Island : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lincoln : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Omaha : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lebanon : Dartmouth Hitchcock Medical Center

SuperNOVA Clinical Stenting Trial

Nashua : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Camden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Elmer : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Freehold : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hackensack : Hackensack University Medical Center

PROMUS Element Plus US Post-Approval Study

Haddon Heights : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

New Brunswick : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ocean : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pomona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Westwood : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Albuquerque : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bronx : Biomedical Research Alliance of New York

Atherosclerotic Lesions

View More »

Binghamton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Endwell : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Liverpool : St. Joseph's Hospital Health Center

SuperNOVA Clinical Stenting Trial

Mineola : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Windsor : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New York : Mount Sinai School of Medicine Hospital

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

New York : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New York : Gotham Cardiovascular Research PC

SmartRisk Stroke Prediction by MRI of Carotid Disease

New York : New York University School of Medicine

SmartRisk Stroke Prediction by MRI of Carotid Disease

Rochester : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Utica : St. Elizabeth Medical Center

PROMUS Element Plus US Post-Approval Study

Williamsville : 115 Flint Road

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

Raleigh : Rex Healthcare

ALERTS (AngeLmed for Early Recognition and Treatment of STEMI) Study

Raleigh : Rex Healthcare

The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

Raleigh : Rex Healthcare

TRANSLATE- Treatment with ADP receptor inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome Registry

View More »

Asheboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Calabash : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Charlotte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Charlotte : Mid-Carolina Cardiology Presbyterian Hospital

PROMUS Element Plus US Post-Approval Study

Charlotte : Mid-Carolina Cardiology Presbyterian Hospital

SuperNOVA Clinical Stenting Trial

Greensboro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greenville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hickory : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pinehurst : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Raleigh : Rex Hospital

SuperNOVA Clinical Stenting Trial

Salisbury : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sanford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Statesville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wilmington : Coastal Surgery Specialists

SuperNOVA Clinical Stenting Trial

Winston-Salem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fargo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Grand Forks : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Akron : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cincinnati : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cincinnati : Metabolic And Atherosclerosis Research Center/ Medpace Clinical Pharmacology

Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins

Cleveland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbus : Ohio State University

Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE)

View More »

Columbus : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbus : Grant Medical Center

SuperNOVA Clinical Stenting Trial

Columbus : Ohio State University Medical Center

SuperNOVA Clinical Stenting Trial

Marion : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bartlesville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oklahoma City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tulsa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tulsa : St. Francis Hospital

PROMUS Element Plus US Post-Approval Study

Bend : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Portland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Portland : OHSU Hospital

Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

Abington : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Allentown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Altoona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beaver : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Camp Hill : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Doylestown : Doylestown Hospital

PROMUS Element Plus US Post-Approval Study

Erie : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Harrisburg : Pinnacle Health Cardiovascular Insititute

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Hershey : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Philadelphia : Presbyterian University of Pennsylvania Medical Center

PROMUS Element Plus US Post-Approval Study

Pittsburgh : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pittsburgh : UPMC - Passavant

SuperNOVA Clinical Stenting Trial

Pottstown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tipton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Uniontown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

York : York Hospital

SuperNOVA Clinical Stenting Trial

Cumberland : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Providence : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Anderson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Charleston : Medical University of South Carolina Hospital

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

Charleston : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Columbia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Greenville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Greenville : St. Francis Health System - St. Francis Hospital

PROMUS Element Plus US Post-Approval Study

Greenville : University Medical Center-Greenville Memorial Hospital

PROMUS Element Plus US Post-Approval Study

Greer : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mt. Pleasant : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Myrtle Beach : Grand Strand Regional Medical Center

PROMUS Element Plus US Post-Approval Study

Ninety Six : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

North Myrtle Beach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Orangeburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rock Hill : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Varnville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rapid City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rapid City : Rapid City Regional Hospital

PROMUS Element Plus US Post-Approval Study

Rapid City : Black Hills Cardiovascular

SuperNOVA Clinical Stenting Trial

Sioux Falls : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sioux Falls : Avera Heart Hospital of South Dakota

PROMUS Element Plus US Post-Approval Study

Germantown : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jackson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Johnson City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Knoxville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Memphis : Methodist North Hospital

SuperNOVA Clinical Stenting Trial

View More »

Nashville : St. Thomas Research Institute, LLC

SuperNOVA Clinical Stenting Trial

Allen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Austin : South Austin Hospital

PROMUS Element Plus US Post-Approval Study

Beaumont : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bedford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dallas : Veterans Affairs North Texas Health Care Systems

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

View More »

Dallas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dallas : VA North Texas Medical Center

PROMUS Element Plus US Post-Approval Study

Dallas : Presbyterian Hospital of Dallas

PROMUS Element Plus US Post-Approval Study

Dallas : VA North Texas Health Care System

SuperNOVA Clinical Stenting Trial

Fort Worth : Heart Center of Northe Texas

SuperNOVA Clinical Stenting Trial

Galveston : University of Texas Medical Branch

SuperNOVA Clinical Stenting Trial

Gonzales : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Houston : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Houston : Baylor College of Medicine

Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions

Houston : Baylor College of Medicine

SmartRisk Stroke Prediction by MRI of Carotid Disease

Irving : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lake Jackson : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leander : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Livingston : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lufkin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Marshall : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

McKinney : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Odessa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pasadena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plano : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Antonio : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Temple : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Waco : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Webster : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bountiful : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Layton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salt Lake City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salt Lake City : Western Institute for Biomedical Research

SmartRisk Stroke Prediction by MRI of Carotid Disease

Burlington : Fletcher Allen Health Care

SuperNOVA Clinical Stenting Trial

Burke : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Danville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ettrick : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Richmond : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Richmond : Chippenham Medical Center

PROMUS Element Plus US Post-Approval Study

View More »

Roanoke : Carilion Roanoke Memorial Hospital

PROMUS Element Plus US Post-Approval Study

Port Orchard : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Renton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seattle : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seattle : Swedish Medical Center

SuperNOVA Clinical Stenting Trial

Seattle : University of Washington Coronary Atherosclerosis Research Lab

Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)

View More »

Silverdale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tacoma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Yakima : Yakima Heart Center

Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)

Morgantown : West Virginia University

SmartRisk Stroke Prediction by MRI of Carotid Disease

Madison : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Madison : Meriter Hospital

PROMUS Element Plus US Post-Approval Study

Wauwatosa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bahía Blanca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Buenos Aires : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Caba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Caba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cipolletti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Cordoba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Córdoba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Corrientes : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Formosa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mar del Plata : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Posadas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Quilmes : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rosario : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Luis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Miguel de Tucuman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Nicolas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Salvador de Jujuy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santa Fe : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santiago del Estero : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tucuman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tucuman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bateman : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Garran : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Geelong : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gosford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heidelberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Hobart : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Joondalup : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kogarah : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Liverpool : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Melbourne : The Alfred

480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions

Milton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Perth : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Southport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Feldbach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Graz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Linz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Moedling : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salzburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

St. Stefan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vienna : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vienne : Allgemeines Krankenhaus AKH

SuperNOVA Clinical Stenting Trial

Wien : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Aalst : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Antwerpen : ZNA Middelheim

Safety and Effectiveness of the Coronary Momo Stent

Bonheiden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bonheiden : Imelda Hospital Cardiovascular & Thoracic Surgery

IN.PACT Global Clinical Study

Bonheiden : Imelda vzw

Safety and Effectiveness of the Coronary Momo Stent

View More »

Bonheiden : Imelda Ziekenhuis

SuperNOVA Clinical Stenting Trial

Brasschaat : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brugge : AZ Sint Jan

Safety and Effectiveness of the Coronary Momo Stent

Brussel : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brussel : UZ Brussel

Safety and Effectiveness of the Coronary Momo Stent

De Pinte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dendermonde : A.Z. Sint-Blasius Vascular Surgery

IN.PACT Global Clinical Study

Edegem : Universitare Ziekenhuis Antwerpen - UZA

IN.PACT Global Clinical Study

Genk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Genk : Ziekenhuis Oost-Limburg

Safety and Effectiveness of the Coronary Momo Stent

Genk : Ziekenhuis Oost Limburg

SuperNOVA Clinical Stenting Trial

Gent : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gent : AZ Maria Middelares

Safety and Effectiveness of the Coronary Momo Stent

Hasselt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Huy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leuven : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mechelen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ottignies : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tienen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tienen : Regionaal Ziekenhuis Heilig Hart Tienen

SuperNOVA Clinical Stenting Trial

Aracajú : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Belem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Belo Horizonte : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Belo Horizonte : Hospital Felicio Rocho

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

Blumenau : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Brasilia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Campinas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Campo Grande : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Curitiba : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Florianópolis : Clinica Coris Medicina Avançada /Baia Sul Medical Center

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

Goiania : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Passo Fundo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pelotas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Porto Alegre : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Recife : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salvador : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Santo Andre : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sao Jose do Rio Preto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sao Paulo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sao Paulo : Heart Institute

Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe

São Paulo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

São Paulo : Irmandade Santa Casa de Misericórdia de São Paulo

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

São Paulo : Instituto Dante Pazzanese de Cardiologia

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

São Paulo : Hospital Santa Marcelina de São Paulo

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

Uberlândia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pazardzhik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pleven : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plovdiv : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sofia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cambridge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Drummondville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gatineau : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Granby : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guelph : Guelph General Hospital

SuperNOVA Clinical Stenting Trial

View More »

Halifax : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Joliette : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kitchener : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lachine : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Laval : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lévis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Longueuil : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Loretteville : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Markham : Lynderm Research Inc.

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

Mississauga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Montreal : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Montreal : Hospital Maisonneuve-Rosemont

SuperNOVA Clinical Stenting Trial

Montreal : Innovaderm Research Inc

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

Mount Pearl : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Westminster : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newmarket : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Peterborough : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Quebec : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Québec : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sainte-Foy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saskatoon : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Scarborough : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sherbrook : Fleurimont Hospital

SuperNOVA Clinical Stenting Trial

Sherbrooke : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ste-Foy : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St-Hyacinthe : Clinique Médicale Dr Isabelle Delorme

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

St-Jean-sur-Richelieu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Surrey : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Terrebonne : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thetford Mines : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thunder Bay : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Toronto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Victoria : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Windsor : Windsor Clinical Research Inc.

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

Winnipeg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Winnipeg : Winnipeg Health Sciences Centre

SuperNOVA Clinical Stenting Trial

Baotou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beijing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Beijing : Cardiology department ,Beijing Anzhen hospital

Fluvastatin AmelIorates aTHerosclerosis Study

Beijing : Chinese PLA General Hospital

Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)

Changsha : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Chongqing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dalian : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guang Zhou City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guangzhou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hangzhou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nanjing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shanghai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shanghai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shenyang : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Suzhou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tianjin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tianjin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wuhan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Xi'an : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Baranquilla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Barranquilla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Barranquilla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bogotá : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucaramanga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Cali : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cartagena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cartegena : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Florida Blanca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Floridablanca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Benesov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Broumov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jablonec nad Nisou : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kladno : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Louny : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Marianske lazne : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Most : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ostrava : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pardubice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Plzen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Prague 4 - Krc : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 11 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 2 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 2 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Praha 9 : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Slany : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Uherske Hradiste : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Usti nad Labem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Usti nad Orlici : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vyskov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Znojmo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Aarhus C : Dep. of Dermatology

Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents

Parnu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saku : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tallinn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tartu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Viljandimaa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Võru : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Limoges : C.H.U. Dupuytren

The eMESH 1 Feasibility Study

Pessac : Bordeaux University Hospital

The eMESH 1 Feasibility Study

Anderbeck : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bad Krozingen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Balve : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Berlin : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Berlin : Center or Diagnostic Radiology and Minimally Invasive Therapy / Gefäßzentrum am JuedischenKrankenhaus

SuperNOVA Clinical Stenting Trial

View More »

Bochum : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Borna : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chemnitz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dillingen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dortmund : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dresden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Duisburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Düsseldorf : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ebersbach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Elsterwerda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Erlangen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Essen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Falkensee : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Flensburg : Ev. Luth. Diakonissenanstalt Flensburg

SuperNOVA Clinical Stenting Trial

Frankfurt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Freiburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fulda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Giengen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Haag : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Halle/'Saale : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hamburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heidelberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heidenau : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heilbronn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jerichow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kallstadt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kamp-Lintfort : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Koblenz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Köln : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kuenzing : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leipzig : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leipzig : Herzzentrum Leipzig GmbH/Park Krankenhaus

SuperNOVA Clinical Stenting Trial

Ludwigshafen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lüneburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mainz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mayen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Meissen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Muehldorf am Inn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Muehlhausen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mühlheim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Munich : Site 01: Department of Neurology, TU Munich

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Münster : Site 03: Universitätsklinikum Münster

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Neuhofen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Neunkirchen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Northeim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nürnberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oelde : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oschatz : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Paderborn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Potsdam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rednitzhembach : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Reinfeld : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rotenburg a.d. Fulda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rüdersdorf : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Siegen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tübingen : Site 04: Universitätsklinikum Tübingen, Klinik für Allgemeine Neurologie

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Tutzing : Site 02: Benedictus Krankenhaus Tutzing GmbH u. Co. KG

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Ulm : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Weinheim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wiesbaden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Witten : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wolmirstedt : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Athens : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Athens - GR : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chaidari : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chalikida : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heraklion : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Magoula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Patras : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Thessaloniki : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Voula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guatemala City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Budapest : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Debrecen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gyula : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kistarcsa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Komarom : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Miskolc : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mosonmagyarovar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nyiregyháza : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pecs : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Szeged : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Szentes : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Zalaegerszeg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kopavogur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Reykjavik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ahmedabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ahmedabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bangalore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bengaluru : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bikaner : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Coimbatore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ghaziabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guntur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hyderabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hyderabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Jaipur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kochi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lucknow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ludhiana : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Madurai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Manipal : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mohali : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nagpur : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nashik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nellore : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Delhi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

New Delhi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pune : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rajasthan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Secunderabad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Surat : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tirupati : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vadodara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Varanasi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vijayawada : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vishakhapatnam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ancona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bergamo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brescia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Casorate Primo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Catanzaro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Chieti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cortona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fermo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Firenze : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Foggia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Massa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Milano : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Monserrato : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Napoli : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Novara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Padova : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Palermo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Parma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pavia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Piacenza : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pisa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pisa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pozzilli : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Roma : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Daniele Del Friuli : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sassari : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Treviglio : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Verona : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Veruno : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amagasaki : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amagasaki-shi : Kansai Rosai Hospital

SuperNOVA Clinical Stenting Trial

Bunkyo-ku : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chiyoda-ku : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Fujioka-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Funabashi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Higashiibaraki-gun : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hirakata-City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hitachi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ichinomiya : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Itabashi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kasuga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kishiwada-shi : Kishiwada Tokushukai Hospital

SuperNOVA Clinical Stenting Trial

Kitakyushu-shi : Kokura Memorial Hospital

SuperNOVA Clinical Stenting Trial

Komatsushima : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kumamoto City : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kurume-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kusatsu-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kyoto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Matsudo-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nagano : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nagaoka-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nagoya : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nishinomiya : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ogaki : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ogura-gun : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Osaka : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Osaka-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sapporo-shi : Tokeidai Memorial Hospital

SuperNOVA Clinical Stenting Trial

Sayama-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sendai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sendai-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seto : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Shinjuku-ku : Tokyo Women's Medical University Hospital

SuperNOVA Clinical Stenting Trial

Takamatsu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Takarazuka-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Takasaki-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Takatsuki : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tokorozawa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Yokohama-city : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Busan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Busan : Inje University Pusan Paik Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Daegu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Daegu : Yeungnam University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Daejeon : Chungnam National University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

View More »

Daejon : Eulji University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Deagu : Kyungpook National University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Gwangju : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gwangju : Chonnam National University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Iksan : Wonkwang University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Inchon : Inha University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Pusan : Dong-A University Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Seoul : Asan Medical Center

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Kyung Hee University Medical Center

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Seoul Medical Center

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Eulji Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Seoul : Boramae Hospital

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Suwon : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Uijeongbu-Si : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Wonju : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Daugavplis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Liepaja : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Riga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Riga : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Valmiera : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Ventspils : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Alytus : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kaunas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kedainiai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Klaipeda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Panevezys : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Siauliai : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vilnius : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Culiacan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Guadalajara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Querétaro : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Luis Potosi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Luis Potosí : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Alkmaar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amersfoort : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amstelveen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amsterdam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Amsterdam : Academic Medical Center

Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI for Carotid Artery Plaque

View More »

Amsterdamn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Apeldoorn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Breda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Deventer : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Doetinchem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ede : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gouda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Groningen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Haarlem : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Heerlen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hoorn : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leeuwarden : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Maastricht : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Meppel : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nijmegen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rotterdam : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sneek : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tiel : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Utrecht : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Venlo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Auckland : Auckland City Hospital

480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions

Ålesund : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Elverum : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hamar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Harstad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hønefoss : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Lillehammer : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lorenskog : Akershus University Hospital

Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy

Lørenskog : Akershus University Hospital

Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease

Moss : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nesttun : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oslo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sandefjord : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skedsmokorset : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Stavanger : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tønsberg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Trondheim : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tynset : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bialystok : Novartis Investigative Site

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Gdansk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Gdynia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kraków : Novartis Investigative Site

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Lódz : Novartis Investigative Site

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

View More »

Olawa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Poznan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rumia : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skierniewice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Warszawa : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Warszawa : Novartis Investigative Site

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Wegrow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Manati : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Mayaguez : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ponce : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

San Juan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Baia Mare : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Braila : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brasov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucharest : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucharest : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Bucharest : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucuresti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucuresti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bucuresti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cluj Napoca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cluj Napoca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cluj-Napoca : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Constanta : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Craiova : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Craiova : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Hunedoara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Iasi : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oradea : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Pitesti : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sibiu : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Targu Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Targu Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Targu Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Targu-Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tg. Mures : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Timisoara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Timisoara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Barnaul : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chelyabinsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ekaterinburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Izhevsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kazan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Kemerovo : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kirov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Krasnodar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Moscow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Novosibirsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Omsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Penza : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Petrozavodsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ryazan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saint Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saint-Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Samara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sankt-Peterburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Saratov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sestroreck : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Smolensk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St. Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St.- Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St.-Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

St-Petersburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Syktyvkar : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tomsk : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Tyumen : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Banska Bystrica : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bardejov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bratislava : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bratislava : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Brezno : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Dubnica nad Vahom : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dunajska Streda : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Galanta : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Komarno : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kosice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kosice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Levice : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lucenec : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nitra : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nove Zamky : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Povazska Bystrica : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Presov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Presov : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rimavska Sobota : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Rimavska Sobota : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Svidnik : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Trnava : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Velky Krtis : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Zilina : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Alberton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bloemfontein : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cape Town : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Durban : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Johannesburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Pretoria : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Verwoerdburg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lleida : Hospital Arnau de Vilanova

Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.

Göteborg : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kristianstad : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Luleå : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lund : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Malmö : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Mölndal : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Östersund : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skanör : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skelleftea : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Skene : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Stockholm : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Uddevalla : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Vällingby : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Västerås : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Bern : University Hospital of Bern

The eMESH 1 Feasibility Study

Lausanne : Service de Chirurgie cardio-vasculaire CHUV

New Anastomotic Device for End to End Vascular Anastomosis in the Treatment of Peripheral Vascular Disease

Changhua : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ilan : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kaohsiung : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Lin-Ko : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Niaosong Township : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Taichung : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Taichung : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Taipei : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Taipei : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Yungkang : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Ankara : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Istanbul : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Izmir : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Kocaeli : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sivas : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Atherstone : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Axbridge : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Barnet : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Basingstoke : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Birmingham : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

View More »

Bristol : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cambridge : Cambridge University Hospitals NHS Foundation Trust

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.

Cardiff : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Carshalton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Cheshire : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Chesterfield : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Dundee : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Exeter : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Glasgow : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Irvine : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Leicester : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

London : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

London : Royal Brompton & Harefield NHS Foundation Trust

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.

Newcastle Upon Tyne : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Newport : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Norwich : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nottingham : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Nottingham : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Oxford : CTSU, University of Oxford

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Penzance : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Salford : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sheffield : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Sheffield : Northern General Hospital

SuperNOVA Clinical Stenting Trial

Taunton : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

West Midlands : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Whitby : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Worcester : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

York : Novartis Investigative Site

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)